2015 American Transplant Congress
Preemptive Deceased Donor Transplant With Kidney Donor Profile Index Scores Greater Than 85 Not Associated With a Survival Benefit
University of Virginia, Charlottesville, VA.
Preemptively listed candidates for kidney transplant are a unique patient population with regard to marginal quality kidney acceptance as they are not yet dialysis dependent.…2015 American Transplant Congress
Role of CMV, BKV, and Immunosupression Non-Adherence in Early and Late De Novo Donor Specific Anti-HLA Antibody Development and Outcomes
This analysis aims to identify appropriate de novo DSA (dnDSA) screening points and delineate the post-transplant (txp) scenarios preceding dnDSA development to aid in clinical…2015 American Transplant Congress
Lung Transplantation from Donors With Kidney Disease
Duke University Medical Center, Durham, NC.
Background:Various donor characteristics are associated with decreased survival following single (SLT) or bilateral (BLT) lung transplantation. No current studies exist regarding use of lungs from…2015 American Transplant Congress
Liver Transplantation for Primary Liver Malignancies Vs. Neuroendocrine Metastases: Analysis of the UNOS Dataset
Objective: To determine outcome in patients undergoing LT for NETs, and compared them with outcomes in patients with primary liver malignancies such as Hepatocellular Carcinoma…2015 American Transplant Congress
Early Clinical Indicators of Long Term Survival and Allograft Loss Following De Novo DSA. A 15-Year Longitudinal Study
Improvement in outcomes in renal transplant patients with de novo donor specific anti-HLA antibodies (dnDSA) is needed. This analysis aims to identify surrogate endpoints following…2015 American Transplant Congress
Multicenter Study to Develop a Novel Prediction Index for Hepatocellular Carcinoma (HCC) Recurrence After Liver Transplant (LT)
1UCSF, San Francisco, CA; 2Mayo Clinic, Rochester, MN; 3Mayo Clinic, Jacksonville, FL.
Several factors have been associated with a high risk of recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT), but no reliable risk score has…2015 American Transplant Congress
The Benefit of Hepatitis C Donor Kidney Transplantation Is Limited to Hepatitis C Positive Patients Over 50 Years of Age
Division of Nephrology, University of British Columbia, Vancouver, BC, Canada.
The purpose of this analysis was to provide information regarding the use and survival benefit of kidney transplantation from a hepatitis C positive deceased donor…2015 American Transplant Congress
Excellent Outcomes With Kidney Transplantation for Patients ≥70 Years of Age
BackgroundOur aim was to determine the outcomes following kidney transplantation in recipients ≥70 years of age at the time of transplantation.Materials and MethodsWe analyzed data…2015 American Transplant Congress
Recurrence of Hepatocellular Carcinoma After Transarterial Chemoembolization (TACE) Alone and TACE in Combination With Other Treatment Modalities
General Surgery, Houston Methodist Hospital, Houston, TX.
AIM:Treatment of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) can help downstage tumors prior to orthotopic liver transplantation (OLT); however, there is a risk of…2015 American Transplant Congress
Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of Graft Failure and Mortality Among Kidney Transplant Recipients
Purpose: Graft loss and death are generally late events after kidney transplantation, and trials designed to assess the impact of interventions on these outcomes are…